Skip to content
Operation Infinite Justice – Lifestyle
Author:
Basilea Pharmaceutica International Ltd, Allschwil
Basilea raises full-year guidance 2026 and financial target for “Agenda 2030” and provides updates on late-stage clinical programs
October 27, 2026
Basilea reports presentation of new data for fosmanogepix, isavuconazole and ceftobiprole at IDWeek 2026
October 20, 2026
Basilea announces start of clinical study by partner Asahi Kasei Therapeutics in Japan with antifungal Cresemba® (isavuconazole) in pediatric patients
September 14, 2026
Basilea reports strong 2026 half-year results and raises full-year guidance; fosmanogepix phase 3 program on track
August 18, 2026
Basilea receives additional USD 5.4 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam
August 5, 2026
Basilea receives USD 30 million funding under existing BARDA agreement for advancing phase 3 development of novel antifungal fosmanogepix
July 29, 2026
Basilea receives further USD 13 million from BARDA to continue development of novel antibiotic ceftibuten-ledaborbactam
May 28, 2026